Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease HELP
Based on 37,144 articles published since 2010
|||| 18 

These are the 37144 published articles about Parkinson Disease that originated from Worldwide during 2010-2020.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Deep brain stimulation in parkinson disease. 2019

Bernardo, Wanderley Marques / Rubira, Claudio / Silvinato, Antonio. ·Brazilian Medical Association, Rua São Carlos do Pinhal, 324 - Bela Vista, São Paulo - SP, Brasil. ·Rev Assoc Med Bras (1992) · Pubmed #31066807.

ABSTRACT: The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize producers to assist the reasoning and decision-making of doctors. The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient.

2 Guideline Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients With Parkinson's Disease: Executive Summary. 2018

Rughani, Anand / Schwalb, Jason M / Sidiropoulos, Christos / Pilitsis, Julie / Ramirez-Zamora, Adolfo / Sweet, Jennifer A / Mittal, Sandeep / Espay, Alberto J / Martinez, Jorge Gonzalez / Abosch, Aviva / Eskandar, Emad / Gross, Robert / Alterman, Ron / Hamani, Clement. ·Neuroscience Institute, Maine Medical Center, Portland, Maine. · Department of Neurosurgery, Henry Ford Medical Gr-oup, West Bloomfield, Michigan. · De-partment of Neurology and Ophthal-mology, Michigan State University, Michigan. · Departments of Neuroscience and Experimental Therapeutics and of Neurosurgery, Albany Medical College, Albany, New York. · Center for Movement Disorders and Neurorestoration, Gain-esville, Florida. · Department of Neuro-surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio. · De-partment of Neurosurgery, Wayne State University, Detroit, Michigan. · James J. and Joan A. Gardner Center for Parkinson Disease and Movement Disorders, University of Cincinnati, Cincinnati, Ohio. · Neurological Institute, Cleveland Clinic, Cleveland, Ohio. · Department of Neurosurgery, University of Colorado School of Medicine, Aurora, Colorado. · Department of Neurological Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. · Department of Neu-rosurgery, Emory University, Atlanta, Georgia. · Division of Neurosurgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massa-chusetts. · Division of Neurosurgery, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. ·Neurosurgery · Pubmed #29538685.

ABSTRACT: QUESTION 1: Is bilateral subthalamic nucleus deep brain stimulation (STN DBS) more, less, or as effective as bilateral globus pallidus internus deep brain stimulation (GPi DBS) in treating motor symptoms of Parkinson's disease, as measured by improvements in Unified Parkinson's Disease Rating Scale, part III (UPDRS-III) scores? RECOMMENDATION: Given that bilateral STN DBS is at least as effective as bilateral GPi DBS in treating motor symptoms of Parkinson's disease (as measured by improvements in UPDRS-III scores), consideration can be given to the selection of either target in patients undergoing surgery to treat motor symptoms. (Level I). QUESTION 2: Is bilateral STN DBS more, less, or as effective as bilateral GPi DBS in allowing reduction of dopaminergic medication in Parkinson's disease? RECOMMENDATION: When the main goal of surgery is reduction of dopaminergic medications in a patient with Parkinson's disease, then bilateral STN DBS should be performed instead of GPi DBS. (Level I). QUESTION 3: Is bilateral STN DBS more, less, or as effective as bilateral GPi DBS in treating dyskinesias associated with Parkinson's disease? RECOMMENDATION: There is insufficient evidence to make a generalizable recommendation regarding the target selection for reduction of dyskinesias. However, when the reduction of medication is not anticipated and there is a goal to reduce the severity of "on" medication dyskinesias, the GPi should be targeted. (Level I). QUESTION 4: Is bilateral STN DBS more, less, or as effective as bilateral GPi DBS in improving quality of life measures in Parkinson's disease? RECOMMENDATION: When considering improvements in quality of life in a patient undergoing DBS for Parkinson's disease, there is no basis to recommend bilateral DBS in 1 target over the other. (Level I). QUESTION 5: Is bilateral STN DBS associated with greater, lesser, or a similar impact on neurocognitive function than bilateral GPi DBS in Parkinson disease? RECOMMENDATION: If there is significant concern about cognitive decline, particularly in regards to processing speed and working memory in a patient undergoing DBS, then the clinician should consider using GPi DBS rather than STN DBS, while taking into consideration other goals of surgery. (Level I). QUESTION 6: Is bilateral STN DBS associated with a higher, lower, or similar risk of mood disturbance than GPi DBS in Parkinson's disease? RECOMMENDATION: If there is significant concern about the risk of depression in a patient undergoing DBS, then the clinician should consider using pallidal rather than STN stimulation, while taking into consideration other goals of surgery. (Level I). QUESTION 7: Is bilateral STN DBS associated with a higher, lower, or similar risk of adverse events compared to GPi DBS in Parkinson's disease? RECOMMENDATION: There is insufficient evidence to recommend bilateral DBS in 1 target over the other in order to minimize the risk of surgical adverse events.  The full guideline can be found at: https://www.cns.org/guidelines/deep-brain-stimulation-parkinsons-disease.

3 Guideline ESPEN guideline clinical nutrition in neurology. 2018

Burgos, Rosa / Bretón, Irene / Cereda, Emanuele / Desport, Jean Claude / Dziewas, Rainer / Genton, Laurence / Gomes, Filomena / Jésus, Pierre / Leischker, Andreas / Muscaritoli, Maurizio / Poulia, Kalliopi-Anna / Preiser, Jean Charles / Van der Marck, Marjolein / Wirth, Rainer / Singer, Pierre / Bischoff, Stephan C. ·Nutritional Support Unit, University Hospital Vall d'Hebron, Barcelona, Spain. Electronic address: rburgos@vhebron.net. · Nutrition Unit, University Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. · Nutrition and Dietetics Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Fondazione Grigioni per il Morbo di Parkinson, Milano, Italy. · Nutrition Unit, ALS Centre, University Hospital of Limoges, Limoges, France. · Department of Neurology, University Hospital Münster, Germany. · Clinical Nutrition, Geneva University Hospitals, Geneva, Switzerland. · Cereneo (Center for Neurology and Rehabilitation) and University Department of Internal Medicine, Kantonsspital Aarau, Switzerland. · Department of Geriatrics, Alexianer Hospital Krefeld, Krefeld, Germany. · Department of Clinical Medicine, Sapienza, University of Rome, Rome, Italy. · Department of Nutrition, Laikon General Hospital, Athens, Greece. · Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium. · Department of Geriatric Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. · Department of Geriatric Medicine, Marien Hospital Herne, Ruhr-University Bochum, Germany. · Department of General Intensive Care and Institute for Nutrition Research, Rabin Medical Center, Beilinson Hospital, Tel Aviv University, Petah Tikva, Israel. · Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany. ·Clin Nutr · Pubmed #29274834.

ABSTRACT: Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may be involved in the pathogenesis of neurological diseases. Multiple causes for the development of malnutrition in patients with neurological diseases are known including oropharyngeal dysphagia, impaired consciousness, perception deficits, cognitive dysfunction, and increased needs. The present evidence- and consensus-based guideline addresses clinical questions on best medical nutrition therapy in patients with neurological diseases. Among them, management of oropharyngeal dysphagia plays a pivotal role. The guideline has been written by a multidisciplinary team and offers 88 recommendations for use in clinical practice for amyotrophic lateral sclerosis, Parkinson's disease, stroke and multiple sclerosis.

4 Guideline Neurogenic bowel dysfunction: Clinical management recommendations of the Neurologic Incontinence Committee of the Fifth International Consultation on Incontinence 2013. 2018

Cotterill, Nikki / Madersbacher, Helmut / Wyndaele, Jean J / Apostolidis, Apostolos / Drake, Marcus J / Gajewski, Jerzy / Heesakkers, John / Panicker, Jalesh / Radziszewski, Piotr / Sakakibara, Ryuji / Sievert, Karl-Dietrich / Hamid, Rizwan / Kessler, Thomas M / Emmanuel, Anton. ·Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK. · University Clinic for Neurourology, Innsbruck, Austria. · University Hospital, Antwerp, Belgium. · Aristotle University of Thessaloniki, Thessaloniki, Greece. · Urology Consultants, Halifax, Canada. · University Medical Center St Radboud, Nijmegen, The Netherlands. · National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. · Medical University of Warsaw, Warsaw, Poland. · Sakura Medical Center, Toho University, Sakura, Japan. · University of Tuebingen, Tuebingen, Germany. · University College London Hospitals, London, UK. · Balgrist University Hospital, Zurich, Switzerland. · St. Mark's Hospital, London, UK. ·Neurourol Urodyn · Pubmed #28640977.

ABSTRACT: BACKGROUND: Evidence-based guidelines for the management of neurological disease and lower bowel dysfunction have been produced by the International Consultations on Incontinence (ICI). These are comprehensive guidelines, and were developed to have world-wide relevance. AIMS: To update clinical management of neurogenic bowel dysfunction from the recommendations of the 4th ICI, 2009. MATERIALS AND METHODS: A series of evidence reviews and updates were performed by members of the working group. The resulting guidelines were presented at the 2012 meeting of the European Association of Urology for consultation, and modifications applied to deliver evidence based conclusions and recommendations for the scientific report of the 5th edition of the ICI in 2013. RESULTS: The current review is a synthesis of the conclusions and recommendations, including the algorithms for initial and specialized management of neurogenic bowel dysfunction. The pathophysiology is described in terms of spinal cord injury, multiple sclerosis, and Parkinson's disease. Assessment requires detailed history and clinical assessment, general investigations, and specialized testing, if required. Treatment primarily focuses on optimizing stool consistency and regulating bowel evacuation to improve quality of life. Symptom management covers conservative and interventional measures to promote good habits and assist stool evacuation, along with prevention of incontinence. Education is essential to achieving optimal bowel management. DISCUSSION: The review offers a pragmatic approach to management in the context of complex pathophysiology and varied evidence base.

5 Guideline Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. 2015

Odin, P / Ray Chaudhuri, K / Slevin, J T / Volkmann, J / Dietrichs, E / Martinez-Martin, P / Krauss, J K / Henriksen, T / Katzenschlager, R / Antonini, A / Rascol, O / Poewe, W / Anonymous2260838. ·Department of Neurology, Lund University Hospital, 221 85 Lund, Sweden; Klinikum-Bremerhaven, D-27574 Bremerhaven, Germany. Electronic address: per.odin@med.lu.se. · King's College London, and National Parkinson Foundation Centre of Excellence, Dept of Neurology, King's College Hospital, London, UK. · Department of Neurology, University of Kentucky College of Medicine, Kentucky Clinic L-445, 740 South Limestone Street, Lexington, KY 40536-0284, USA. · Department of Neurology, University Hospital of Würzburg, 97080 Würzburg, Germany. · Department of Neurology, Oslo University Hospital and University of Oslo, N-0424 Oslo, Norway. · National Center for Epidemiology and CIBERNED, ISCIII, Avenida Monforte de Lemos 5, 28029 Madrid, Spain. · Department of Neurosurgery, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. · University Hospital of Bispebjerg, Bispebjerg Bakke 23, 2400 København, NV, Denmark. · Department of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Sozialmedizinisches Zentrum Ost - Donauspital, 1220 Wien Langobardenstraße 122, Austria. · Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, Italy. · Clinical Investigation Center 1436 and Department of Clinical Pharmacology, INSERM and University Hospital of Toulouse, Toulouse University, 37 alées Jules Giesde, 31000 Toulouse, France; Clinical Investigation Center 1436 and Department of Neurosciences, INSERM and University Hospital of Toulouse, Toulouse University, 37 alées Jules Giesde, 31000 Toulouse, France. · Innsbruck Medical University/University Hospital, Anichstrasse 35, A-6020 Innsbruck, Austria. ·Parkinsonism Relat Disord · Pubmed #26233582.

ABSTRACT: Navigate PD was an educational program established to supplement existing guidelines and provide recommendations on the management of Parkinson's disease (PD) refractory to oral/transdermal therapies. It involved 103 experts from 13 countries overseen by an International Steering Committee (ISC) of 13 movement disorder specialists. The ISC identified 71 clinical questions important for device-aided management of PD. Fifty-six experts responded to a web-based survey, rating 15 questions as 'critically important;' these were refined to 10 questions by the ISC to be addressed through available evidence and expert opinion. Draft guidance was presented at international/national meetings and revised based on feedback. Key take-home points are: • Patients requiring levodopa >5 times daily who have severe, troublesome 'off' periods (>1-2 h/day) despite optimal oral/transdermal levodopa or non-levodopa-based therapies should be referred for specialist assessment even if disease duration is <4 years. • Cognitive decline related to non-motor fluctuations is an indication for device-aided therapies. If cognitive impairment is mild, use deep brain stimulation (DBS) with caution. For patients who have cognitive impairment or dementia, intrajejunal levodopa infusion is considered as both therapeutic and palliative in some countries. Falls are linked to cognitive decline and are likely to become more frequent with device-aided therapies. • Insufficient control of motor complications (or drug-resistant tremor in the case of DBS) are indications for device-aided therapies. Levodopa-carbidopa intestinal gel infusions or subcutaneous apomorphine pump may be considered for patients aged >70 years who have mild or moderate cognitive impairment, severe depression or other contraindications to DBS.

6 Guideline Consensus statements on driving in people with Parkinson's disease. 2014

Classen, Sherrilene / Anonymous510792 / Anonymous520792. ·School of Occupational Therapy, Elborn College, Western University, London, Ontario, Canada. ·Occup Ther Health Care · Pubmed #24754762.

ABSTRACT: Parkinson's disease (PD) is a complex neurodegenerative disorder leading to motor and non-motor impairments, all of which can affect fitness to drive. The literature suggest that on-road and simulated driving performances are impaired in people with PD, as compared to healthy control drivers. Clear associations exist between impaired driving performance and contrast sensitivity, visual processing speed, and psychomotor speed. Prior to this review and expert panel process, no evidence-based guidelines have existed to help occupational therapy practitioners determining fitness to drive in those with PD. Three consensus statements are presented in this work to enable occupational therapy practitioners and other driver rehabilitation specialists to make fitness to drive determinations in people with PD.

7 Guideline Consensus-based clinical practice recommendations for the examination and management of falls in patients with Parkinson's disease. 2014

van der Marck, Marjolein A / Klok, Margit Ph C / Okun, Michael S / Giladi, Nir / Munneke, Marten / Bloem, Bastiaan R / Anonymous4210783. ·Radboud university medical center, Nijmegen Centre for Evidence Based Practice, Department of Neurology, Nijmegen, The Netherlands. · University of Florida Center for Movement Disorders and Neurorestoration, Gainesville, FL, USA. · Movement Disorders Unit, Department of Neurology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. · Radboud university medical center, Nijmegen Centre for Evidence Based Practice, Department of Neurology, Nijmegen, The Netherlands; Radboud university medical center, Nijmegen Centre for Evidence Based Practice, Scientific Institute for Quality of Healthcare, Nijmegen, The Netherlands. · Radboud university medical center, Donders Institute for Brain, Cognition and Behavior, Department of Neurology, Nijmegen, The Netherlands. Electronic address: Bas.Bloem@radboudumc.nl. ·Parkinsonism Relat Disord · Pubmed #24484618.

ABSTRACT: Falls in Parkinson's disease (PD) are common and frequently devastating. Falls prevention is an urgent priority, but there is no accepted program that specifically addresses the risk profile in PD. Therefore, we aimed to provide consensus-based clinical practice recommendations that systematically address potential fall risk factors in PD. We developed an overview of both generic (age-related) and PD-specific factors. For each factor, we specified: best method of ascertainment; disciplines that should be involved in assessment and treatment; and which interventions could be engaged. Using a web-based tool, we asked 27 clinically active professionals from multiple relevant disciplines to evaluate this overview. The revised version was subsequently reviewed by 12 experts. Risk factors and their associated interventions were included in the final set of recommendations when at least 66% of reviewing experts agreed. These recommendations included 31 risk factors. Nearly all required a multidisciplinary team approach, usually involving a neurologist and PD-nurse specialist. Finally, the expert panel proposed to first identify the specific fall type and to tailor screening and treatment accordingly. A routine evaluation of all risk factors remains reserved for high-risk patients without prior falls, or for patients with seemingly unexplained falls. In conclusion, this project produced a set of consensus-based clinical practice recommendations for the examination and management of falls in PD. These may be used in two ways: for pragmatic use in current clinical practice, pending further evidence; and as the active intervention in clinical trials, aiming to evaluate the effectiveness and cost-effectiveness of large scale implementation.

8 Guideline Brazilian Medical Association guidelines for the diagnosis and differential diagnosis of panic disorder. 2013

Levitan, Michelle Nigri / Chagas, Marcos H / Linares, Ila M / Crippa, José A / Terra, Mauro B / Giglio, Alcir T / Cordeiro, Joana L C / Garcia, Giovana J / Hasan, Rosa / Andrada, Nathalia C / Nardi, Antonio E. ·Laboratory of Panic & Respiration, Institute of Psychiatry, Universidade Federal do Rio de Janeiro (UFRJ), Rio de JaneiroRJ, Brazil. · Department of Neurosciences and Behavioral Sciences, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão PretoSP, Brazil. · Department of Clinical Medicine: Psychiatry, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto AlegreRS, Brazil. · Centro de Estudos Jose de Barros Falcão, Porto AlegreRS, Brazil. · Associação Brasileira de Neurologia, Associação Brasileira de NeurologiaBrazil, Brazil. · Associação Médica Brasileira, Associação Médica BrasileiraBrazil, Brazil. ·Braz J Psychiatry · Pubmed #24402216.

ABSTRACT: OBJECTIVE: To present the most relevant findings regarding the Brazilian Medical Association guidelines for the diagnosis and differential diagnosis of panic disorder. METHODS: We used the methodology proposed by the Brazilian Medical Association for the Diretrizes Project. The MEDLINE (PubMed), Scopus, Web of Science, and LILACS online databases were queried for articles published from 1980 to 2012. Searchable questions were structured using the PICO format (acronym for "patient" [or population], "intervention" [or exposure], "comparison" [or control], and "outcome"). RESULTS: We present data on clinical manifestations and implications of panic disorder and its association with depression, drug abuse, dependence and anxiety disorders. In addition, discussions were held on the main psychiatric and clinical differential diagnoses. CONCLUSIONS: The guidelines are proposed to serve as a reference for the general practitioner and specialist to assist in and facilitate the diagnosis of panic disorder.

9 Guideline Managing impulse control behaviours in Parkinson's disease: practical guidelines. 2013

Macphee, Graeme J A / Chaudhuri, K Ray / David, Anthony S / Worth, Paul / Wood, Brian. ·Southern General Hospital, Glasgow, UK. graeme.macphee@ggc.scot.nhs.uk ·Br J Hosp Med (Lond) · Pubmed #23665786.

ABSTRACT: -- No abstract --

10 Guideline Canadian Guidelines on Parkinson's Disease. 2012

Grimes, David / Gordon, Joyce / Snelgrove, Barbara / Lim-Carter, Ivy / Fon, Edward / Martin, Wayne / Wieler, Marguerite / Suchowersky, Oksana / Rajput, Alex / Lafontaine, Anne L / Stoessl, Jon / Moro, Elena / Schoffer, Kerrie / Miyasaki, Janis / Hobson, Doug / Mahmoudi, Minoo / Fox, Susan / Postuma, Ron / Kumar, Hrishikesh / Jog, Mandar / Anonymous2770741. ·Ottawa Hospital, University of Ottawa, Ottawa, Canada. dagrimes@ottawahospital.on.ca ·Can J Neurol Sci · Pubmed #23126020.

ABSTRACT: -- No abstract --

11 Guideline EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. 2012

Sorbi, S / Hort, J / Erkinjuntti, T / Fladby, T / Gainotti, G / Gurvit, H / Nacmias, B / Pasquier, F / Popescu, B O / Rektorova, I / Religa, D / Rusina, R / Rossor, M / Schmidt, R / Stefanova, E / Warren, J D / Scheltens, P / Anonymous1620734. ·Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy. sorbi@unifi.it ·Eur J Neurol · Pubmed #22891773.

ABSTRACT: BACKGROUND AND OBJECTIVES: The last version of the EFNS dementia guidelines is from 2007. In 2010, the revised guidelines for Alzheimer's disease (AD) were published. The current guidelines involve the revision of the dementia syndromes outside of AD, notably vascular cognitive impairment, frontotemporal lobar degeneration, dementia with Lewy bodies, corticobasal syndrome, progressive supranuclear palsy, Parkinson's disease dementia, Huntington's disease, prion diseases, normal-pressure hydrocephalus, limbic encephalitis and other toxic and metabolic disorders. The aim is to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists and other specialist physicians responsible for the care of patients with dementing disorders. It represents a statement of minimum desirable standards for practice guidance. METHODS: The task force working group reviewed evidence from original research articles, meta-analyses and systematic reviews, published by June 2011. The evidence was classified (I, II, III, IV) and consensus recommendations graded (A, B, or C) according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. RESULTS AND CONCLUSIONS: New recommendations and good practice points are made for clinical diagnosis, blood tests, neuropsychology, neuroimaging, electroencephalography, cerebrospinal fluid (CSF) analysis, genetic testing, disclosure of diagnosis, treatment of behavioural and psychological symptoms in dementia, legal issues, counselling and support for caregivers. All recommendations were revised as compared with the previous EFNS guidelines. The specialist neurologist together with primary care physicians play an important role in the assessment, interpretation and treatment of symptoms, disability and needs of dementia patients.

12 Guideline Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. 2010

Zesiewicz, T A / Sullivan, K L / Arnulf, I / Chaudhuri, K R / Morgan, J C / Gronseth, G S / Miyasaki, J / Iverson, D J / Weiner, W J / Anonymous2050653. ·University of South Florida, Tampa, USA. ·Neurology · Pubmed #20231670.

ABSTRACT: OBJECTIVE: Nonmotor symptoms (sleep dysfunction, sensory symptoms, autonomic dysfunction, mood disorders, and cognitive abnormalities) in Parkinson disease (PD) are a major cause of morbidity, yet are often underrecognized. This evidence-based practice parameter evaluates treatment options for the nonmotor symptoms of PD. Articles pertaining to cognitive and mood dysfunction in PD, as well as treatment of sialorrhea with botulinum toxin, were previously reviewed as part of American Academy of Neurology practice parameters and were not included here. METHODS: A literature search of MEDLINE, EMBASE, and Science Citation Index was performed to identify clinical trials in patients with nonmotor symptoms of PD published between 1966 and August 2008. Articles were classified according to a 4-tiered level of evidence scheme and recommendations were based on the level of evidence. RESULTS AND RECOMMENDATIONS: Sildenafil citrate (50 mg) may be considered to treat erectile dysfunction in patients with Parkinson disease (PD) (Level C). Macrogol (polyethylene glycol) may be considered to treat constipation in patients with PD (Level C). The use of levodopa/carbidopa probably decreases the frequency of spontaneous nighttime leg movements, and should be considered to treat periodic limb movements of sleep in patients with PD (Level B). There is insufficient evidence to support or refute specific treatments for urinary incontinence, orthostatic hypotension, and anxiety (Level U). Future research should include concerted and interdisciplinary efforts toward finding treatments for nonmotor symptoms of PD.

13 Editorial If not salivary alpha-synuclein, then what? A look at potential Parkinson's disease biomarkers. 2020

Bougea, Anastasia. ·1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. ·Expert Rev Mol Diagn · Pubmed #31986922.

ABSTRACT: -- No abstract --

14 Editorial Deep brain stimulation for Parkinson disease - What does the short-term outcome analysis tell us? 2020

Ba, Fang / Siddiqui, Junaid. ·Division of Neurology, Department of Medicine, University of Alberta, 7-131 Clinical Sciences Building, 11350 - 83 Avenue, Edmonton, Alberta, T6G 2G3, Canada. Electronic address: fb@ualberta.ca. · University of Missouri- School of Medicine, University of Missouri Health Care, 531, CS&E Building, 1 Hospital Drive, Columbia, MO, 65212, USA. Electronic address: SiddiquiJ@health.missouri.edu. ·Parkinsonism Relat Disord · Pubmed #31831380.

ABSTRACT: -- No abstract --

15 Editorial Editorial: Innovative Technologies and Clinical Applications for Invasive and Non-invasive Neuromodulation: From the Workbench to the Bedside. 2019

Bologna, Matteo / Merola, Aristide / Ricciardi, Lucia. ·Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy. · IRCCS Neuromed, Pozzilli, Italy. · Department of Neurology, Wexner Medical Center, The Ohio State University, Columbus, OH, United States. · Neurosciences Research Centre, Molecular and Clinical Sciences Research Institute, St. George's University of London, London, United Kingdom. ·Front Neurol · Pubmed #31998215.

ABSTRACT: -- No abstract --

16 Editorial Editorial: The Role of the Basal Ganglia in Somatosensory-Motor Interactions: Evidence From Neurophysiology and Behavior. 2019

Beudel, Martijn / Macerollo, Antonella / Brown, Matt J N / Chen, Robert. ·Department of Neurology, Amsterdam Neuroscience Institute, Amsterdam University Medical Centre, Amsterdam, Netherlands. · School of Psychology, University of Liverpool, Liverpool, United Kingdom. · Department of Kinesiology, California State University Sacramento, Sacramento, CA, United States. · Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada. ·Front Hum Neurosci · Pubmed #31969811.

ABSTRACT: -- No abstract --

17 Editorial Editorial: Integrative Approach to Parkinson's Disease. 2019

Kim, Seung-Nam / Wang, Xiaomin / Park, Hi-Joon. ·College of Korean Medicine, Dongguk University, Goyang, South Korea. · Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China. · College of Korean Medicine, Kyung Hee University, Seoul, South Korea. ·Front Aging Neurosci · Pubmed #31920622.

ABSTRACT: -- No abstract --

18 Editorial Editorial: Mitochondrial Dysfunction and Neurodegeneration. 2019

Tapias, Victor. ·Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, United States. ·Front Neurosci · Pubmed #31920522.

ABSTRACT: -- No abstract --

19 Editorial The Eighth ECS Workshop on "Calcium Signaling in Aging and Neurodegenerative Diseases". 2019

Parys, Jan B / Pereira, Cláudia F / Villalobos, Carlos. ·KU Leuven, Laboratory for Molecular and Cellular Signaling, Department of Cellular and Molecular Medicine, Campus Gasthuisberg O/N-1 B-802, Herestraat 49, 3000 Leuven, Belgium. · Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Rua Larga, Faculty of Medicine, Polo I, 1st Floor, 3004-504 Coimbra, Portugal. · CIBB-Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Rua Larga, Faculty of Medicine, Polo I, 1st Floor, 3004-504 Coimbra, Portugal. · Faculty of Medicine, Azinhaga de Santa Comba, Celas, 3000-548 Coimbra, Portugal. · Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid y Consejo Superior de Investigaciones Científicas (CSIC), 47003 Valladolid, Spain. ·Int J Mol Sci · Pubmed #31842284.

ABSTRACT: The European Calcium Society (ECS) is very glad to present the realization of a special issue of the International Journal of Molecular Sciences (IJMS) related to the eighth ECS workshop organized this year around the theme of "Calcium Signaling in Aging and Neurodegenerative Diseases" [...].

20 Editorial Editorial: Mitochondria and Endoplasmic Reticulum Dysfunction in Parkinson's Disease. 2019

Barodia, Sandeep Kumar / Prabhakaran, Krishnan / Karunakaran, Smitha / Mishra, Vikas / Tapias, Victor. ·Center for Neurodegeneration and Experimental Therapeutics, Birmingham, AL, United States. · Department of Biology, Norfolk State University, Norfolk, VA, United States. · Centre for Brain Research, Indian Institute of Science, Bangalore, India. · Department of Pharmaceutical Sciences, Basanaheb Bhirao Ambedkar University, Lucknow, India. · Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, United States. ·Front Neurosci · Pubmed #31780882.

ABSTRACT: -- No abstract --

21 Editorial Editorial to "Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study" by Friedman et al. 2019

Friedman, Joseph H / Violante, Mayela Rodriguez / Miyasaki, Janis M. ·Department of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, USA. Electronic address: Joseph_friedman@brown.edu. · Laboratorio Clinico de Enfermedades Neurodegenerativas, Instituo Nacional de Neuroligia y Neurocirugia, Mexico. Electronic address: mrodriguez@innn.edu.mx. · Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. Electronic address: miyasaki@ualberta.ca. ·Parkinsonism Relat Disord · Pubmed #31759870.

ABSTRACT: -- No abstract --

22 Editorial Perivascular spaces in basal ganglia - An innocent bystander in Parkinson's disease? 2019

Rundek, Tatjana / Shpiner, Danielle S / Margolesky, Jason. ·Department of Neurology and the Evelyn F. McKnight Brain Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. ·Mov Disord · Pubmed #31743510.

ABSTRACT: -- No abstract --

23 Editorial Editorial: Current State of Postural Research - Beyond Automatic Behavior. 2019

Keshner, Emily A / Fung, Joyce. ·Department of Health and Rehabilitation Sciences, Temple University, Philadelphia, PA, United States. · School of Physical and Occupational Therapy, McGill University, Montreal, QC, Canada. ·Front Neurol · Pubmed #31736864.

ABSTRACT: -- No abstract --

24 Editorial Editorial: New Advances in Neurorehabilitation. 2019

Tamburin, Stefano / Smania, Nicola / Saltuari, Leopold / Hoemberg, Volker / Sandrini, Giorgio. ·Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. · Neuromotor and Cognitive Rehabilitation Research Centre, University of Verona, Verona, Italy. · Research Unit for Neurorehabilitation South Tyrol, Bolzano, Italy. · Department of Neurology, State Hospital Hochzirl, Zirl, Austria. · Department of Neurology, Stiftung Rehabilitation Heidelberg Gesundheitszentrum Bad Wimpfen GmbH, Bad Wimpfen, Germany. · Neurorehabilitation Unit, Istituto di Ricovero e Cura a Carattere Scientifico C. Mondino Foundation, Pavia, Italy. · Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. ·Front Neurol · Pubmed #31681155.

ABSTRACT: -- No abstract --

25 Editorial 5-HT 2019

Kwan, Cynthia / Huot, Philippe. ·Neurodegenerative Disease Group, Montreal Neurological Institute, H3A 2B4 Montreal, QC, Canada. · Department of Neurology & Neurosurgery, McGill University, H3A 2B4 Montreal, QC, Canada. · Department of Neuroscience, McGill University Health Centre, H3A 2B4 Montreal, QC, Canada. ·Neurodegener Dis Manag · Pubmed #31580227.

ABSTRACT: -- No abstract --